Long-term efficacy of ocrelizumab in the treatment of patients with multiple sclerosis – case reports

Author:

Krzystanek Ewa1ORCID,Brola Waldemar2ORCID,Wnuk Marcin3ORCID

Affiliation:

1. Katedra i Klinika Neurologii, Wydział Nauk o Zdrowiu w Katowicach, Śląski Uniwersytet Medyczny, Katowice, Polska

2. Zakład Neurologii, Collegium Medicum, Uniwersytet Jana Kochanowskiego w Kielcach, Kielce, Polska

3. Katedra i Klinika Neurologii, Uniwersytet Jagielloński Collegium Medicum, Kraków, Polska; Oddział Kliniczny Neurologii, Szpital Uniwersytecki w Krakowie, Kraków, Polska

Abstract

Treatment of patients with multiple sclerosis, despite the availability of many therapies, remains a challenge. The introduction of ocrelizumab, a highly effective therapy, has significantly improved the control of disease activity. The article discusses four different cases of patients treated with ocrelizumab, including one patient with newly diagnosed relapsing-remitting multiple sclerosis, one case of treatment modification after ineffective first-line therapy, and two cases of long-term follow-up of patients with primary progressive multiple sclerosis. The review of case studies is complemented by magnetic resonance images and the results of tests evaluating treatment effectiveness. In all clinical situations discussed, ocrelizumab proved to be the optimal choice. In addition to inhibiting the clinical and radiological progression of the disease in the long term, it was very well tolerated by patients.

Publisher

Medical Communications Sp. z.o.o.

Reference15 articles.

1. Arnold DL, Traboulsee A, Wolinsky JS et al.: Long-term suppression of MRI disease activity and reduction of global/regional volume loss: results from OPERA I/II and ORATORIO open-label extension. Presented at ECTRIMS 2021. P407.

2. Bonek R: Specjalne warianty kliniczne. In: Bonek R (ed.): Stwardnienie rozsiane. Od chemokin do przeciwciał monoklonalnych. PZWL Wydawnictwo Lekarskie, Warszawa 2020: 143–193.

3. Brown JWL, Coles A, Horakova D et al.; MSBase Study Group: Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019; 321: 175–187.

4. Cerqueira J, Berthele A, Cree B et al.: Long-term treatment with first-line ocrelizumab in patients with early RMS: 9-year OPERA subgroup analysis (S46.002). Neurology 2023; 100 (17_supplement_2).

5. Espiritu A, Oh J: Prognostic factors in multiple sclerosis. Pract Neurol 2022; February: 44–48.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3